ACIU 4.95 -43% 7:02 am ET *AC Immune Reports Genentech Disclosed That The Anti-Tau Antibody Did Not Meet The Co-primary Efficacy Endpoint Or Two Secondary Endpoints In The Tauriel Study; The Primary Safety Endpoint Was Met Benzinga
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.